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The quantitative or qualitative decline of high-density lipoprotein (HDL) is linked to the pathogenesis of atherosclerosis because of its
antiatherogenic functions, including the mediation of reverse cholesterol transport from the peripheral cells to the liver. We have recently
shown that group X secretory phospholipase A2 (sPLA2-X) is involved in the pathogenesis of atherosclerosis via potent lipolysis of low-
density lipoprotein (LDL) leading to macrophage foam cell formation. We demonstrate here that sPLA2-X as well as group V secretory PLA2
(sPLA2-V), another group of sPLA2 that can potently hydrolyze phosphatidylcholine (PC), also possess potent hydrolytic potency for PC in
HDL linked to the production of a large amount of unsaturated fatty acids and lysophosphatidylcholine (lysoPC). In contrast, the classical
types of group IB and IIA secretory PLA2s evoked little, if any, lypolytic modification of HDL. Treatment with sPLA2-X or -Valso caused an
increase in the negative charge of HDL with no oxidation and little modification of apolipoprotein AI (apoAI). Modification with sPLA2-X or
-V resulted in significant decrease in the capacity of HDL to cause cellular cholesterol efflux from lipid-loaded macrophages.
Immunohistochemical analysis revealed significant expression of sPLA2-X in foam cell lesions in the arterial intima of Watanabe heritable
hyperlipidemic (WHHL) rabbit. These findings suggest that lipolytic modification of HDL by sPLA2-X or -V causes drastic change of HDL
in terms of the production of a large amount of unsaturated fatty acids and lysoPC linked to the reduction of its antiatherogenic functions.
These sPLA2-mediated modifications of plasma lipoproteins might be relevant to the pathogenesis of atherosclerosis.
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lesterol transport, a process by which HDL can remove and
deliver excess cholesterol from the peripheral cells to the
liver [2,3]. The first and essential step in this transport is the
cholesterol efflux from plasma membranes of peripheral
cells to HDL, with the phospholipid content and composi-
tion in HDL being a major factor determining the capacity
of cholesterol efflux [4]. By stimulation of the cellular
cholesterol efflux from arterial macrophages, HDL can
inhibit the formation of foam cells that play an important
role in fatty streak formation as well as in the formation of
the complex lesions of plaque rupture [5]. Therefore, the
loss of antiatherogenic functions of HDL by either qualita-
tive or quantitative reduction can cause the generation and
progression of atherosclerosis.
Y. Ishimoto et al. / Biochimica et Biophysica Acta 1642 (2003) 129–138130Phospholipase A2s (PLA2s) are a diverse family of
lipolytic enzymes that hydrolyze the sn-2 fatty acid ester
bond of glycerophospholipids to produce free fatty acids
and lysophospholipids [6,7]. Among them, secretory PLA2s
(sPLA2s) have several characteristics including a low mo-
lecular mass (13–18 kDa) and an absolute catalytic require-
ment for millimolar concentrations of Ca2 + [8,9], and are
now classified into nine different groups in humans (IB, IIA,
IID, IIE, IIF, III, V, X and XII) [8,10–12]. A variety of
circumstantial evidence suggests that sPLA2-induced hydro-
lysis of phospholipids in HDL plays a role in modulating
HDL metabolism and function. For example, snake venom
sPLA2 can hydrolyze HDL phospholipids and alter the size
and density, as well as the capacity of cholesterol efflux of
HDL [4], resulting in increased uptake by rat hepatocytes
[13]. Among the endogenous sPLA2s, marked expression of
group IIA sPLA2 (sPLA2-IIA) has been reported in athero-
sclerotic lesions in humans [14]. In addition, sPLA2-IIA-
transgenic mice exhibit decreased levels of HDL concom-
itant with increased atherosclerotic lesions [15]. Gesquiere
et al. [16] have recently reported that group V sPLA2
(sPLA2-V) has a potent hydrolyzing activity toward phos-
phatidylcholine (PC) and can induce the release of fatty
acids from HDL more potently than sPLA2-IIA. Although
there are few reports on sPLA2-V expression in atheroscre-
lotic lesions, these observations strongly suggest that the
sPLA2 family of enzymes may be involved in the develop-
ment of atherosclerosis via their lipolytic activity on HDL.
Recently, we and other groups have shown that group X
sPLA2 (sPLA2-X) is one of the enzymes that possesses
potent hydrolyzing activity toward PC [17]. In fact, sPLA2-
X can induce potent release of arachidonic acid leading to
cyclooxygenase-dependent prostaglandin formation, as well
as marked production of lysophosphatidylcholine (lysoPC)
in various cell types, including macrophages, spleen cells
and colon cancer cells [18–20]. More recently, we have
shown that sPLA2-X can induce potent lipolysis of low-
density lipoprotein (LDL) leading to the production of large
amounts of unsaturated fatty acids and lysoPC [21]. The
sPLA2-X-modified LDL was efficiently incorporated into
macrophages to induce the accumulation of cellular choles-
terol ester and the formation of non-membrane-bound lipid
droplets in the cytoplasm [21]. These findings prompted us
to examine the lipolytic effects of sPLA2-X on HDL
functions.
In the present study, we first evaluated the potencies of
sPLA2s with respect to the release of fatty acids and the
contents of PC and lysoPC in HDL. We then compared the
characteristics of sPLA2-modified HDL with oxidized HDL
in terms of phospholipid composition, negative charge and
apolipoprotein AI (apoAI) modification. We found that
sPLA2-X as well as sPLA2-V can induce potent lipolysis
of HDL leading to the reduction of its capacity for choles-
terol efflux from lipid-loaded macrophages. We also report
on the elevated expression of sPLA2-X in the foam cells in
the atherosclerotic arterial wall of Watanabe heritable hyper-lipidemic (WHHL) rabbit that is commonly used as the
animal model of atherogenesis [22].2. Materials and methods
Purified recombinant proteins of human sPLA2-IB,
sPLA2-V and sPLA2-X were prepared as described previ-
ously [17,19]. Recombinant human sPLA2-IIA was a gen-
erous gift from Dr. Ruth Kramer (Eli Lilly, Indianapolis,
USA). Rabbit anti-human sPLA2-X antibody (Ab) was
prepared as described previously [19], and anti-sPLA2-IB
and anti-sPLA2-IIA Abs were purchased from Cayman
Chemicals. Bovine serum albumin (BSA) was obtained
from Sigma. Indoxam was synthesized at Shionogi Re-
search Laboratories [23].
2.1. Preparation of human HDL and modification with
sPLA2s and CuSO4 oxidation
Human HDL (d = 1.085–1.21 g/ml) was isolated from
the plasma of healthy and fasting donors by sequential
ultracentrifugation, as described previously [24]. For
modification of HDL with sPLA2s, 1 mg/ml HDL was
incubated with various concentrations of sPLA2-IB, -IIA
or -X at 37 jC in buffer composed of 1 mM CaCl2, 12.5
mM Tris–HCl (pH 8.0), 0.25 M NaCl and 0.0125%
BSA. The reaction was stopped by addition of EDTA at
the final concentration of 5 mM. For oxidative modifi-
cation, 1 mg/ml HDL was incubated with 20 AM CuSO4
at 37 jC, and then dialyzed against 150 mM NaCl
containing 0.24 mM EDTA (pH 7.4). HDL prepared by
incubation without any modification was used as native
HDL.
2.2. Measurement of released fatty acids, PC and lysoPC in
sPLA2-treated HDL
Human HDL (1 mg/ml) was preincubated for 10 min at
37 jC and incubated with various concentrations of sPLA2
enzymes in a final volume of 40 Al. The reaction was
stopped by the addition of 160 Al of Dole’s reagent, and
the released fatty acids were extracted, labeled with 9-
anthryldiazomethane (Funakoshi Co.), and then analyzed
by reverse-phase HPLC on a LiChroCART 125-4 Super-
sphere 100 RP-18 column (Merck), as described previously
[17,25].
For measurement of the amounts of PC and lysoPC in
HDL, lipids were extracted with organic solvent, as de-
scribed previously [18]. The extracted phospholipids were
then separated by normal-phase HPLC on Ultrasphere silica
4.6 250 mm (Beckman) connected with a guard column of
4.6 45 mm using a solvent of acetonitrile/methanol/sulfu-
ric acid (100:7:0.05, v/v/v) with a flow rate of 1 ml/min at
room temperature. Fractions corresponding to authentic PC
or L-a-lysoPC (Sigma), detected at the wavelength of 202
Fig. 1. Profiles of fatty acids released from HDL by the action of human
sPLA2s. HDL (1 mg/ml) was incubated with 50 nM purified human sPLA2s
for 4 h at 37 jC, and the released fatty acids were quantified as described
under Section 2.2. Each point represents the meanF S.D. of triplicate
measurements. The data are representative of three experiments.
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analysis [26].
2.3. Analysis of oxidation in HDL modified with sPLA2s and
CuSO4
Following the modification with sPLA2s and CuSO4
oxidation, lipid peroxidation was assessed by the following
procedures. The peroxides were quantified in terms of
thiobarbituric acid-reactive substances (TBARS) according
to the methods of Nagano et al. [27].
2.4. Analysis of electronic charge and apoAI in HDL
modified with sPLA2s and oxidation
The electrophoretic mobility of HDL was analyzed with
agarose gel electrophoresis (TITAN GEL Lipoproteins;
Helena Laboratories, Japan), as described previously [28].
For analysis of apoAI modification, HDL was delipidated
and analyzed by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) in 4% acrylamide, as described previously
[29].
2.5. Measurement of cholesterol efflux by HDL from
macrophage foam cells
Mouse resident peritoneal macrophages were obtained
from the peritoneal cavity of female ICR mice (8 weeks).
The cells were washed, resuspended in DMEM (Sigma)
containing 10% FCS, and plated in 24-well plate (Costar)
(5 105 cells/well). Non-adherent cells were removed by
washing, and adherent cells were incubated with acetyl LDL
at 50 Ag/ml for 24 h. After incubation, the foamy macro-
phages were rinsed and incubated with DMEM containing
0.1% BSA for 24 h. Next, the macrophages were rinsed and
incubated with either native or modified HDL at 100 Ag/ml
for 24 h. The lipid extracts of the macrophages were
prepared, evaporated, dissolved with isopropanol and the
cholesterol mass was quantified by enzyme fluorometry
[30]. The amount of esterified cholesterol was calculated
by subtracting the free cholesterol from total cholesterol.
The amounts of cellular proteins were quantified with a
BCA Protein Assay reagent (PIERCE) after dissolving the
cells in 0.2 N NaOH.
2.6. Immunohistochemistry
WHHL rabbits and New Zealand White (NZW) rabbits
(8 months old) were sacrificed under pentobarbital anesthe-
sia. Tissue samples were dissected from the aortic arch,
thoracic, and abdominal aorta. They were immersion-fixed
for 4 h in 4% paraformaldehyde, 0.1 M phosphate buffer,
pH 7.2, and embedded in paraffin. Sections of paraffin-
embedded tissues were mounted onto polylysine-coated
slides, dewaxed in xylene, rehydrated in alcohol, and
blocked for endogenous peroxidase (0.3% H2O2 in metha-nol). For sPLA2-IIA and macrophage immunohistochemis-
try, sections were reacted with monoclonal mouse anti-
sPLA2-IIA Ab (5 Ag/ml) (Cayman; Ann Arbor MI) or
monoclonal anti-rabbit macrophage Ab (1:200 dilution)
(RAM-11, Dako, Carpinteria, CA), and immunoreaction
was localized by using a Vectastain ABC kit (Vector
Laboratories; Burlingame, CA). For sPLA2-X immunohis-
tochemistry, the sections were subjected to reaction with
biotin-conjugated rabbit anti-sPLA2-X Ab (17 Ag/ml), and
immunoreaction was detected using tyramide signal ampli-
fication (TSA Biotin System; NEN Life Science Products,
Boston, MA) and visualized with the peroxidase substrate,
3,3V-diaminobenzidine. The sections were counterstained
with hematoxylin.3. Results
3.1. Potent release of unsaturated fatty acids from HDL by
sPLA2-X or -V
We first examined the potency of four types of human
sPLA2 (sPLA2-IB, -IIA, -V and -X at a concentration of 50
nM) for the release of fatty acids from human plasma HDL
within 3 h. As shown in Fig. 1, sPLA2-X induced a marked
release of various types of unsaturated fatty acids in human
HDL in the following order: linoleic acid (C18:2)>arach-
idonic acid (C20:4)>oleic acid (C18:1)>docosahexaenoic
acid (C22:6). sPLA2-V also released various types of
unsaturated fatty acids from HDL, especially linoleic acid
and oleic acid. sPLA2-X and -V elicited the release of these
unsaturated fatty acids in a dose-dependent manner, and
significant release could be detected at values as low as 5
nM (data not shown). Almost all of the released fatty acids
are composed of these four types of fatty acids with little
production of other types of unsaturated and saturated fatty
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the treatments with sPLA2-V and -X (data not shown).
As shown in Fig. 2A, sPLA2-X induced a time-depen-
dent release of unsaturated fatty acids from HDL, and the
release response was almost saturated within 3 h. sPLA2-V
also induced the release of unsaturated fatty acids with a
similar time-dependency, but the total amount was slightly
smaller than that of sPLA2-X especially within 6 h. sPLA2-
IB was found to evoke a small but significant release of fatty
acid only at 24 h. In contrast, there was little, if any, release
with sPLA2-IIA and CuSO4 treatment for 24 h. When
focused on the arachidonic acid release (Fig. 2B), sPLA2-Fig. 2. Time-dependent release of unsaturated fatty acids and dose-
dependent release of arachidonic acid by sPLA2s in HDL. (A) Time-
dependent release of unsaturated fatty acids by human sPLA2s. HDL (1 mg/
ml) was incubated with 50 nM purified human sPLA2s for various times at
37 jC. (B) Dose-dependent release of arachidonic acid by human sPLA2s.
HDL (1 mg/ml) was incubated with various concentrations of purified
human sPLA2s for 1 h at 37 jC. The released fatty acids were quantified as
described under Section 2.2. The results were shown after subtracting the
values obtained with incubation in the absence of sPLA2s at each time
point. The total amounts of four types of unsaturated fatty acids (oleic acid,
linoleic acid, arachidonic acid and docosahexaenoic acid) were shown in
panel A. Each point represents the meanF S.D. of triplicate measurements.
The data are representative of three experiments.
Fig. 3. Effects of human sPLA2s and Cu
2 +-oxidation on PC and lysoPC
contents in HDL. (A) Effects on PC content in HDL. HDL (1 mg/ml) was
incubated with 50 nM purified human sPLA2s or 20 AM CuSO4 for various
times at 37 jC, and the amount of PC was measured as described under
Section 2.2. The results are expressed as the percentage of the amount of
PC present in HDL with no treatment at each time point (300–400 nmol/
mg protein). (B) Effects on lysoPC content. After incubation, the amount of
lysoPC was measured as described under Section 2.2. Each point represents
the meanF S.D. of triplicate measurements. The data are representative of
three experiments.X induced the most potent release among the sPLA2s
examined. Although sPLA2-V released almost the same
level of total fatty acids from HDL, its potency for the
release of arachidonic acid was much lower compared to
sPLA2-X. These results demonstrate that sPLA2-X and
sPLA2-V could elicit potent release of unsaturated fatty
acids from human HDL with different substrate specificities.
3.2. Effects of sPLA2-X and -V on the PC and lysoPC
contents in HDL
Since PC is a major component of phospholipids in HDL,
we next examined the PC content in HDL after treatment with
sPLA2s and CuSO4. As shown in Fig. 3A, the amount of PC
in HDL time-dependently decreased after treatment with
Fig. 4. Agarose gel electrophoresis of HDL treated with human sPLA2s or
CuSO4. HDL (1 mg/ml) was incubated with 50 nM purified human sPLA2s
(IB, IIA, V or X) or 20 AM CuSO4 (Cu2 +) for the indicated times, and the
electrophoretic mobility was analyzed by agarose gel electrophoresis (25
min at 90 V) followed by staining with fat red 7B.
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in HDL by these treatments within 3–6 h, and PC was
completely degraded after 24 h treatment. Corresponding to
the marked reduction of PC contents, a large amount of
lysoPC was produced in HDL by treatment with sPLA2-X
or -V within 3 h (Fig. 3B). Incubation with sPLA2-specific
inhibitor Indoxam (10 AM), which can block the enzymatic
activities of both sPLA2s [17], resulted in significant sup-
pression of their lipolytic effects on HDL (data not shown).
The time-dependency of PC degradation and lysoPC produc-
tion by sPLA2-X and -V were correlated well with that of
fatty acid releases (Fig. 2A). Despite the similar PC degra-
dation, the amount of lysoPC produced during oxidation by
CuSO4 was only about 15% of that induced by sPLA2-X or -
V. In contrast, treatment with sPLA2-IB or -IIA caused little
change in both PC and lysoPC contents in HDL.
Treatment of HDL with CuSO4 caused a dramatic
increase in TBARS (Table 1) as well as significant produc-
tion of conjugated dienes (data not shown), whereas treat-
ment with four types of sPLA2s did not alter these oxidative
parameters. These findings demonstrate that sPLA2-X and -
V induce PC hydrolysis in HDL leading to the production of
a large amount of lysoPC and unsaturated fatty acids
without any oxidative modification.
3.3. Effect of sPLA2-X and -V on electronic mobility and
apoAI in HDL
We next examined the effects of sPLA2 treatment on the
electronic charge of HDL with agarose gel electrophoresis.
As shown in Fig. 4, increased anodic migration was ob-
served in HDL after 24 h oxidation with CuSO4. Treatment
with sPLA2-X or -V also caused enhanced mobility of HDL
and marked migration was detected even after 3 h of
incubation. In contrast, the mobility of HDL after treatment
with sPLA2-IB or -IIA was not changed during 24 h of
incubation. Addition of anti-sPLA2-X Ab (100 Ag/ml),
which was proven to inhibit the enzymatic activity of
sPLA2-X [17], resulted in complete blockade of sPLA2-X-Table 1
Amounts of conjugated dienes and TBARS in HDL treated with human
sPLA2s or CuSO4
Treatment TBARS (nmol/mg protein)
None 4.26F 1.97
sPLA2-IB 4.40F 1.53
sPLA2-IIA 3.58F 1.92
sPLA2-V 3.60F 0.57
sPLA2-X 5.29F 1.76
CuSO4 32.79F 5.56*
Human HDL was incubated with 50 nM human sPLA2s or 20 AM CuSO4
for 24 h at 37 jC, and the amounts of conjugated dienes and TBARS were
measured as described under Section 2.2. Each point of conjugated diene
represents the mean value of triplicate measurements and each point of
TBARS represents the meanF S.D. of triplicate measurements. The data
are representative of three experiments.
*P< 0.01.induced mobilization (data not shown). SDS-PAGE analysis
has also revealed little, if any, denaturation of apoAI after
sPLA2-X or -V treatments for 24 h, which contrasted with
an exaggerated aggregation of apoAI in CuSO4-treated HDL
(data not shown). These results demonstrate that sPLA2-X
and -V can induce an increase of the negative charge of
HDL without any modification of apoAI.
3.4. Effect of sPLA2-X and -V on cellular cholesterol efflux
by HDL
One of the most important functions for antiatherogenic
property of HDL is the mediation of cellular cholesterol
efflux, and the characteristics of phospholipids in HDL in
terms of contents and composition is a major factor deter-
mining the cholesterol efflux capacity from the cells to HDL
[4]. Since sPLA2-X or -V treatment cause a dramatic
decrease in PC along with the increase in lysoPC, we
compared the cholesterol efflux capacity between native
and modified HDL from acetyl LDL-pretreated macro-
phages that accumulated cholesterol ester in the cytoplasm.
As shown in Fig. 5, incubation with native HDL (100 Ag/
ml) resulted in ca. 83% decrease in the mass of cholesteryl
ester accumulated in the lipid-loaded macrophages, and
sPLA2-IB or -IIA-treated HDL possessed a similar efficacy.
In contrast, sPLA2-X or -V-modified HDL caused only
about 60% reduction, indicating a significant decrease in
the capacity to mediate cholesterol efflux. At 50 Ag/ml of
HDL, similar decrease in cellular cholesterol efflux could be
detected in sPLA2-X or -V-modified HDL (data not shown).
These results suggest that sPLA2-X and -V can deprive
HDL of the capacity to induce cholesterol efflux by causing
the alteration of the phospholipid content and composition
in HDL.
3.5. Expression of sPLA2-X in atherosclerotic lesions of
WHHL rabbits
In order to examine the localization of sPLA2-X in the
atherosclerotic lesions, we used WHHL rabbits, a familiar
model of atherogenesis [22]. Fig. 6A shows atherosclerotic
lesions in the aorta of WHHL rabbits. Large foam cells filled
with numerous lipid droplets and cholesterol crystals were
observed between the middle and deep parts of the intimal
Fig. 6. Immunostaining of atherogenic lesions of WHHL rabbits with anti-sPLA2
WHHL rabbits were stained with Elastica-van-Gieson (A) or immunostained with
X Ab (C) or mouse anti-sPLA2-IIA Ab (D). Dark-brown deposits indicated the
hematoxylin. The bar indicates 100 Am.
Fig. 5. Measurement of cholesterol efflux by HDL from lipid loaded
macrophages. Mouse resident peritoneal macrophages were incubated
with acetyl LDL to form foam cells. After incubation with DMEM for 24
h, the macrophages were incubated with either native or modified HDL at
100 Ag/ml for 24 h. At the end of the incubation, the cholesterol mass of
the macrophages was quantified. The amount of esterified cholesterol was
calculated by subtracting the free cholesterol from total cholesterol. Each
point represents the meanF S.D. of triplicate measurements. The data are
representative of three experiments. Statistical significance was deter-
mined by Student’s t-test (*P< 0.05 compared to macrophages treated
with native HDL).
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intimal thickening was found (data not shown). Fig. 6B
shows the result of immunostaining of WHHL aorta with a
monoclonal Ab against rabbit macrophage, RAM-11. Cells
with foam cell morphology were intensely stained with
RAM-11.
To analyze the expression of sPLA2-X in atherosclerotic
lesion by immunohistochemistry, we used biotinylated rab-
bit anti-human sPLA2-X polyclonal Ab. By ELISA and
immunoblotting analysis, we confirmed that this Ab specif-
ically binds to human sPLA2-X with no cross-reactivity for
other human sPLA2s (-IB, -IIA, and -V) and also recognizes
rabbit sPLA2-X (data not shown). Polyclonal anti-sPLA2-X
Ab stained the foam cells in the intima (Fig. 6C), and
immunoreaction was diffuse through the middle to deep
region of the intima, with most of the foam cells being
positive. Moderate staining was also found in the endothe-
lium, but it was non-specific because preincubation of the
Ab with 50-fold (in the molar ratio) excess amount of
recombinant rabbit sPLA2-X completely abolished the stain-
ing of foam cells, but not that of the endothelium (data not
shown). No immunoreaction of sPLA2-X was found in
atherosclerosis-free aorta from NZW rabbits.-X Ab. Paraffin-embedded aorta sections with atherosclerotic lesions from
mouse anti-rabbit macrophage Ab (B), biotin-conjugated rabbit anti-sPLA2-
occurrence of immunoreaction, and the nuclei were counterstained with
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mouse anti-human sPLA2-IIA monoclonal Ab. By immu-
noblotting analysis, we confirmed that this Ab specifically
binds to sPLA2-IIAwith no cross-reactivity for other human
sPLA2s (-IB, -V and -X), as well as rabbit sPLA2-X (data
not shown). Prior to immunostaining of aorta, we tested the
availability of the Ab using rabbit jejunum sections as a
positive control. We detected positive signals in Paneth cells
that have been reported to extensively express sPLA2-IIA in
rats and humans [31,32], demonstrating that the anti-human
sPLA2-IIA Ab we used could cross-react with the counter-
part of rabbit origin. As shown in Fig. 6D, positive cells
were detected in the middle to deep region of the intima and
had the morphology of foam cells. There was great variation
in the degree of immunoreactivity among the foam cells in
the lesion from intense staining to total absence of staining.
These staining patterns of sPLA2-X and -IIA were similar
among the aortic arch, thoracic, and abdominal aorta (data
not shown), indicating that both sPLA2-X and -IIA are
expressed in foamy macrophages in the atherosclerotic
lesions of WHHL rabbits.4. Discussion
Epidemiological studies have established that plasma
HDL concentrations are inversely related to the develop-
ment of coronary heart disease [33]. The formation of
atherosclerotic lesions regressed by infusion of HDL to
cholesterol-fed rabbits [34] and transgenic mice overex-
pressing human apoAI showed an increased plasma level
of HDL and resisted atherosclerosis induced by high-fat diet
[35] or apolipoprotein E (apoE) deficiency [36]. Thus, the
loss of antiatherogenic functions of HDL as well as the
decline of plasma HDL concentration is linked to the
increase in the risk of developing atherosclerosis. In the
present study, we have shown that sPLA2-X and -V induced
a potent lipolytic modification of HDL including complete
hydrolysis of PC linked to the production of large amounts
of unsaturated fatty acids and lysoPC. sPLA2-X or -V-
modified HDL shows features in common with oxidized
HDL in terms of the reduction of PC as well as an increase
in the negative charge. However, marked differences were
observed in several aspects between these modifications.
The increase in lysoPC production during sPLA2-X or -V
treatment was accompanied by the release of large amounts
of unsaturated fatty acids, whereas there was no release
response during HDL oxidation. Higher levels of lysoPC
production were detected in sPLA2-X or -V-treated HDL
compared to oxidized HDL despite a similar PC degradation
(Fig. 3). As lysoPC is believed to play an important role in
atherosclerosis and inflammatory diseases by altering vari-
ous cellular functions, such as the induction of various
chemokines and cell adhesion molecules [37,38], sPLA2-
X or -V-modified HDL might evoke more proatherogenic
cellular events compared to oxidized HDL.It has been known that scavenger receptor B type I (SR-
BI) can act as the HDL receptor to stimulate cholesterol
efflux from foamy macrophages, and the efflux rate is
correlated with SR-BI expression levels in various cell lines
[39]. In the SR-BI-mediated cholesterol efflux, phospholi-
pids present in the acceptor HDL are essential factors,
because the cholesterol efflux is highly correlated with the
concentration of HDL phospholipids in serum and stimu-
lated by phospholipid supplementation of serum [40]. Since
sPLA2-X and -V induced strong degradation of PC, a major
component of phospholipids in HDL, the reduction of the
capacity to induce cellular cholesterol efflux in sPLA2-X or
-V-modified HDL (Fig. 6) might be due to a decrease in the
SR-BI-mediated responses. Alternatively, the ATP-binding
cassette transporter ABCA1 might be involved in this
process, as it has been known to mediate the transport of
cellular cholesterol to lipid-poor HDL apolipoproteins
[41,42]. In fact, mutations in ABCA1 cause Tangier disease
[41,43–45], a severe HDL deficiency syndrome character-
ized by deposition of cholesterol in tissue macrophages and
prevalent atherosclerosis [46]. Recent studies have shown
that unsaturated fatty acids reduce the macrophage ABCA1
content by enhancing its degradation rate [47]. As sPLA2-X
and -V can release a large amount of unsaturated fatty acids
from HDL (Fig. 1), these fatty acids might reduce the
ABCA1 content in macrophages leading to decline of the
cellular cholesterol efflux. Since HDL possesses various
antiatherogenic functions, including the protection of LDL
from oxidation [48–50], the inhibition of platelet aggrega-
tion [51,52] and the protection of endothelial cells from
oxidative stress and apoptosis [53], the effects of sPLA2-X
or -V modification on these biological events should also be
examined in future studies.
Among the human sPLA2s examined, potent lipolysis of
HDL was observed only on treatment with sPLA2-X and -V,
which may have been due to higher hydrolyzing activity
toward PC, the major phospholipid species in HDL [17,54].
Weak fatty acid release was detected during treatment of
HDL with higher concentrations of sPLA2-IB (Fig. 2).
However, sPLA2-IB is mainly expressed in the pancreas
and its expression was not detected in the atherosclerotic
lesions of humans [55] and apoE-deficient mice [21],
indicating that its role in atherogenesis is quite minor. With
regard to sPLA2-IIA, its expression was markedly elevated
in human atherosclerotic arterial intima, where most of the
sPLA2-IIA is localized along the extracellular matrix, asso-
ciated with collagen fibers and other structures [56,57]. In
the present study, we found that sPLA2-IIA is expressed in a
small population of foam cells in the intimal lesion of
WHHL rabbits (Fig. 6D). This observation is consistent
with the report by Menschikowski et al. [14], in which the
expression of sPLA2-IIA was detected in some, but not all,
foam cells in human atherosclerotic plaques. In contrast, the
expression of sPLA2-X was detected in the foam cells
throughout the atherosclerotic intima in WHHL rabbits
(Fig. 6C), similar to its distribution in high-fat fed apoE-
Y. Ishimoto et al. / Biochimica et Biophysica Acta 1642 (2003) 129–138136deficient mice [21]. The different localizations between
sPLA2-IIA and -X suggests their distinct pathophysiological
roles in the initiation and progression of atherosclerotic
plaques. We found that the potency of sPLA2-IIA in HDL
modification in terms of PC degradation and cellular func-
tions is much lower than sPLA2-X, and this type of sPLA2
has been shown to induce the enhanced retention of lip-
oproteins to human aortic proteoglycans [58,59]. These
findings suggest that sPLA2-IIA is involved in the accumu-
lation of extracellular lipoproteins in the proteoglycan-rich
subendothelial layer of the arterial intima, whereas sPLA2-V
and -X induce more powerful lipolysis of HDL linked to the
reduction of its antiatherogenic effect within the arterial
intima. Recent studies have shown that overexpression of
sPLA2-IIA resulted in increased rate of catabolism and
altered sites of tissue uptake of HDL in mice [60]. The
contribution of sPLA2-X to HDL modifications in patho-
logical states should also be clarified in future genetic
studies including the generation of mice deficient in
sPLA2-X.
In the present study, sPLA2-V was also found to hydro-
lyze PC in HDL and release a large amount of unsaturated
fatty acids. However, as reported by Gesquiere et al. [16],
sPLA2-V released more linoleic acid (over 10-fold) than
arachidonic acid from HDL (Fig. 1), which corresponded
well with its fatty acid specificity using synthetic substrate
[61]. In contrast, sPLA2-X can induce potent release of
arachidonic acid from HDL with over half the levels of
linoleic acid (Fig. 1), and its potency for arachidonic acid
release was much higher than sPLA2-V (Fig. 2B), suggest-
ing its greater relevance to the production of proatherogenic
eicosanoids [62,63]. Although sPLA2-V is secreted by
macrophages and mast cells [64], there have been few
reports on its expression in pathological states including
atheroscrelotic lesions. This may be due to the difficulty of
generating sPLA2-V-specific Ab applicable for immunohis-
tochemistry, as many Abs for sPLA2-IIA have been shown
to cross-react with sPLA2-V because of their structural
similarity [64]. In the present study, we confirmed no
cross-reactivity of anti-sPLA2-IIA Ab for human sPLA2-
IB, -V and -X, as well as rabbit sPLA2-X. However, there
was no data showing the absence of its cross-reactivity with
rabbit sPLA2-V, suggesting that positive signals detected in
the atherosclerotic lesions in WHHL rabbits might also
represent the expression of this enzyme. Nevertheless, these
observations strongly suggest that sPLA2 family enzymes
may be involved in the development of atherosclerosis via
modification of HDL.
In conclusion, we have demonstrated here that sPLA2-X
or -V can induce lipolytic modification of HDL leading to a
decrease in its ability to mediate the cellular cholesterol
efflux. Since sPLA2-X and -V can also evoke potent
modification of LDL [16,21], these sPLA2s may be respon-
sible for the generation of atherogenic lipoprotein particles
leading to the formation and progression of fatty streaks in
atherosclerotic regions. In addition, a variety of lipid medi-ators including polyunsaturated fatty acids, eicosanoids and
lysoPC can be generated during the lipolytic process of
lipoproteins, which may also contribute to the progression
of atherosclerosis. Further studies regarding the expression
of sPLA2-X or -V in human atherosclerotic lesions as well
as its circulating levels in patients with atherosclerosis are
required for further understanding of its pathological roles in
humans as well as the strategies of sPLA2 inhibitors as
antiatherogenic drugs.Acknowledgements
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